Argent BiopharmaRGTLF 3-Year ROIIC % is 9.18 as of Jun. 2025. The stock has 8 warning signs investors should review. Among 942 Drug Manufacturers companies, Argent Biopharma ranks better than 58.92% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Argent Biopharma's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 9.18%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Argent Biopharma's 3-Year ROIIC % or its related term are showing as below:
RGTLF's 3-Year ROIIC % is ranked better than 58.92% of 942
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs RGTLF: 9.18
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Argent Biopharma 3-Year ROIIC % Related Terms
Argent Biopharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's 3-Year ROIIC % falls into.
Argent Biopharma's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -10.054 (Jun. 2025) - -10.022 (Jun. 2022) )
/
( 5.518 (Jun. 2025) - 15.002 (Jun. 2022) )
=
-0.032
/
-9.484
=
0.34%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Argent Biopharma (RGTLF) has a 3-Year ROIIC % of 9.18 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Argent Biopharma and its competitors. According to the industry distribution chart, Argent Biopharma ranks #387 out of 942 companies in the Drug Manufacturers industry, placing it in the top 41.1%.
Is Argent Biopharma's 3-Year ROIIC % too high?
Argent Biopharma's current 3-Year ROIIC % is 9.18. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Argent Biopharma's value of 9.18 is 146.8% above this industry median. Based on the distribution chart, Argent Biopharma ranks #387 out of 942 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Argent Biopharma's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #387 out of 942 companies for 3-Year ROIIC %. This puts Argent Biopharma in the upper half of its industry. The industry median 3-Year ROIIC % is 3.72. Argent Biopharma's value of 9.18 is 146.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Argent Biopharma's current 3-Year ROIIC % of 9.18 is 146.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Argent Biopharma and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current 3-Year ROIIC % is 9.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current 3-Year ROIIC % is 9.18 and 146.8% above the Drug Manufacturers industry median of 3.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current 3-Year ROIIC % is 9.18 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 